Congestive Heart Failure Market to Exhibit Rapid Growth Rate During the Forecast Period (2022-2032), Investigates DelveInsight | Key Companies – Otsuka pharmaceuticals, Cytokinetics, AstraZeneca

Posted on
by

Congestive Heart Failure Market to Exhibit Rapid Growth Rate During the Forecast Period (2022-2032), Investigates DelveInsight | Key Companies - Otsuka pharmaceuticals, Cytokinetics, AstraZeneca
DelveInsight’s “Congestive Heart Failure Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Congestive Heart Failure.

DelveInsight’s “Congestive Heart Failure Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Congestive Heart Failure, historical and forecasted epidemiology as well as the Congestive Heart Failure market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

To Know in detail about the Congestive Heart Failure market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Congestive Heart Failure Market Forecast

 

Some of the key facts of the Congestive Heart Failure Market Report: 

  • The Congestive Heart Failure market size was valued approximately USD 6,741 Million in 2021 and is anticipated to grow with a significant CAGR during the study period (2019-2032)
  • In the United States, there were 6,543,570 instances of heart failure overall in 2021. In the US, there will be 5,234,856 cases of documented heart failure overall, according to estimates for 2021
  • In January 2021, Following a hospitalization for heart failure, Merck said that the US FDA had approved Verquvo, a soluble guanylate cyclase (sGC)stimulator, to lower the risk of cardiovascular death and heart failure hospitalization
  • In August 2021, The US FDA has approved Jardiance (empagliflozin) 10 mg, and Boehringer Ingelheim and Eli Lilly reported that it has decreased the risk of cardiovascular death as well as hospitalization for heart failure in individuals with heart failure with reduced ejection fraction (HFrEF)
  • The US is expected to have 2,669,777, 1,533,813, 523,486, and 523,486 cases of class I (no symptoms and no limitations in usual physical activity), class II (mild symptoms and minimal limitations during usual activity), class III (marked limitations in activity due to symptoms, even during less than usual activity), and class IV (severe limitations) in 2021
  • Key Congestive Heart Failure Companies: Otsuka pharmaceuticals, Cytokinetics, AstraZeneca, General Electric Company, Boston Scientific Corporation, Medtronic, St. Jude Medical, Inc., Biotronik SE & Co. KG, LivaNova PLC, Shree Pacetronix Ltd., OSCOR Inc., MEDICO S.p.A., Lepu Medical Technology Co. Ltd., MicroPort Scientific Corporation, Edwards Lifesciences, Zoll Medical Corporation, Vitatron, Osypka Medical, Inc., Cook Medical, Abbott, CorWave SA, Berlin Heart GmbH, Jarvik Heart, Inc., and others
  • Key Congestive Heart Failure Therapies: OPC-61815, Omecamtivmecarbil, AZD4831, AT-001, Rexlemestrocel-L (Revascor), Finerenone (Kerendia), Sotagliflozin, Furoscix(furosemide injection), and others
  • The Congestive Heart Failure epidemiology based on gender analyzed that heart failure is an important cause of morbidity and mortality in women, and the patients tend to develop it at an older age compared to men
  • The Congestive Heart Failure market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Congestive Heart Failure pipeline products will significantly revolutionize the Congestive Heart Failure market dynamics.

 

Congestive Heart Failure Overview

Congestive heart failure (HF) is another name for HF. It can also be divided into right-side HF (occurs when the heart is unable to fill itself with adequate blood) and left-side HF (occurs when the heart is unable to pump enough oxygen-rich blood to the body). Cor pulmonale is another word for heart failure and denotes that the right-side heart failure is brought on by elevated blood pressure in the pulmonary arteries and right ventricle. When the heart struggles to pump enough blood to sustain other organs in the body, some patients experience HF.

 

Get a Free sample for the Congestive Heart Failure Market Report 

https://www.delveinsight.com/sample-request/congestive-heart-failure-market

 

Congestive Heart Failure Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Congestive Heart Failure Epidemiology Segmentation:

The Congestive Heart Failure market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalence of Congestive Heart Failure
  • Prevalent Cases of Congestive Heart Failure by severity
  • Gender-specific Prevalence of Congestive Heart Failure
  • Diagnosed Cases of Episodic and Chronic Congestive Heart Failure

 

Download the report to understand which factors are driving Congestive Heart Failure epidemiology trends @ Congestive Heart Failure Epidemiology Forecast

 

Congestive Heart Failure Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Congestive Heart Failure market or expected to get launched during the study period. The analysis covers Congestive Heart Failure market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Congestive Heart Failure Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Congestive Heart Failure Therapies and Key Companies

  • OPC-61815: Otsuka pharmaceuticals
  • Omecamtivmecarbil: Cytokinetics
  • AZD4831: AstraZeneca
  • AT-001: Applied Therapeutics
  • Rexlemestrocel-L (Revascor): Mesoblast
  • Finerenone (Kerendia): Bayer
  • Sotagliflozin: Lexicon Pharmaceuticals
  • Furoscix(furosemide injection): scPharmaceuticals

 

Discover more about therapies set to grab major Congestive Heart Failure market share @ Congestive Heart Failure Treatment Market

 

Congestive Heart Failure Market Drivers

  • Robust emerging pipeline
  • Recent approval of therapies and promising emerging therapies
  • Evidence-based therapies
  • Aging of the population
  • Rising prevalence of the disease

 

Congestive Heart Failure Market Barriers

  • Availability of generic and off-label therapies in the market setting
  • Lack of confidence in diagnosis and management
  • Treatment failure to stimulate and follow society’s goals and requirements

 

Scope of the Congestive Heart Failure Market Report

  • Study Period: 2019–2032
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Congestive Heart Failure Companies: Otsuka pharmaceuticals, Cytokinetics, AstraZeneca, General Electric Company, Boston Scientific Corporation, Medtronic, St. Jude Medical, Inc., Biotronik SE & Co. KG, LivaNova PLC, Shree Pacetronix Ltd., OSCOR Inc., MEDICO S.p.A., Lepu Medical Technology Co. Ltd., MicroPort Scientific Corporation, Edwards Lifesciences, Zoll Medical Corporation, Vitatron, Osypka Medical, Inc., Cook Medical, Abbott, CorWave SA, Berlin Heart GmbH, Jarvik Heart, Inc., and others
  • Key Congestive Heart Failure Therapies: OPC-61815, Omecamtivmecarbil, AZD4831, AT-001, Rexlemestrocel-L (Revascor), Finerenone (Kerendia), Sotagliflozin, Furoscix(furosemide injection), and others
  • Congestive Heart Failure Therapeutic Assessment: Congestive Heart Failure current marketed and Congestive Heart Failure emerging therapies
  • Congestive Heart Failure Market Dynamics: Congestive Heart Failure market drivers and Congestive Heart Failure market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Congestive Heart Failure Unmet Needs, KOL’s views, Analyst’s views, Congestive Heart Failure Market Access and Reimbursement 

 

To know more about Congestive Heart Failure companies working in the treatment market, visit @ Congestive Heart Failure Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Congestive Heart Failure Market Report Introduction

2. Executive Summary for Congestive Heart Failure

3. SWOT analysis of Congestive Heart Failure

4. Congestive Heart Failure Patient Share (%) Overview at a Glance

5. Congestive Heart Failure Market Overview at a Glance

6. Congestive Heart Failure Disease Background and Overview

7. Congestive Heart Failure Epidemiology and Patient Population

8. Country-Specific Patient Population of Congestive Heart Failure 

9. Congestive Heart Failure Current Treatment and Medical Practices

10. Congestive Heart Failure Unmet Needs

11. Congestive Heart Failure Emerging Therapies

12. Congestive Heart Failure Market Outlook

13. Country-Wise Congestive Heart Failure Market Analysis (2019–2032)

14. Congestive Heart Failure Market Access and Reimbursement of Therapies

15. Congestive Heart Failure Market Drivers

16. Congestive Heart Failure Market Barriers

17.  Congestive Heart Failure Appendix

18. Congestive Heart Failure Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services